Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. NXGL
NXGL logo

NXGL Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
0.665
Open
0.665
VWAP
0.62
Vol
140.89K
Mkt Cap
4.95M
Low
0.577
Amount
86.88K
EV/EBITDA(TTM)
--
Total Shares
8.14M
EV
5.34M
EV/OCF(TTM)
--
P/S(TTM)
0.40
NexGel, Inc. is a provider of healthcare, beauty, and over-the-counter products, including ultra-gentle, high-water-content hydrogels. It is engaged in manufacturing high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. It specializes in custom gels by capitalizing on proprietary manufacturing technologies. The Company operates through two segments: NexGel and CGN. Its Nexgel segment comprises the manufacturing of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, which is based in Langhorne, Pennsylvania. Its CGN segment comprises CG Converting and Packaging, LLC (CGN), a joint venture with C.G. Laboratories Inc. (CG Labs) used for the Company’s converting and packaging business, which is based in Granbury, Texas. Its brands include Silverseal, Hexagels, Turfguard, Kenkoderm, and Silly George.
Show More

Events Timeline

(ET)
2026-03-12
09:00:00
NexGel Acquires Celularity Biomaterials for $15 Million
select
2026-03-12
08:40:00
Celularity Signs Strategic Partnership with NEXGEL
select
2026-03-10 (ET)
2026-03-10
08:50:00
NexGel Signs Agreement to Acquire Celularity's Regenerative Biomaterials
select
2026-02-10 (ET)
2026-02-10
09:10:00
NEXGEL Announces $1.797M Financing for Potential Acquisition
select
2025-12-16 (ET)
2025-12-16
08:10:00
NEXGEL Announces Strategic Investment in NexGelRx
select
2025-12-11 (ET)
2025-12-11
08:20:00
NEXGEL Spins Off Drug Delivery Assets into NexGelRx
select
2025-08-05 (ET)
2025-08-05
08:21:00
NexGel appoints Steve Ciardiello to board of directors
select
2025-08-01 (ET)
2025-08-01
08:04:49
NexGel prices 413,044 shares at $2.30 in registered direct offering
select
2025-07-14 (ET)
2025-07-14
09:03:46
NexGel, STADA announce expansion of partnership for North America
select

News

Newsfilter
9.5
03-25Newsfilter
NEXGEL Schedules Q4 and FY 2025 Earnings Call
  • Earnings Release Schedule: NEXGEL will report its financial results for the fiscal year 2025 and Q4 on March 31, 2026, after market close, reflecting the company's ongoing commitment to transparency and investor communication.
  • Conference Call Timing: Following the earnings release, the company will host a conference call at 4:30 PM ET on the same day, providing investors with a direct opportunity to engage with management and enhance market confidence in the company's future prospects.
  • Replay Availability: For investors unable to attend the live call, NEXGEL offers a replay service available until April 14, 2026, ensuring all stakeholders can access critical information, thereby improving information accessibility.
  • Company Background: NEXGEL specializes in healthcare, beauty, and OTC products, with over two decades of experience in developing electron-beam cross-linked hydrogels, showcasing its leadership position and technological expertise in the industry.
moomoo
7.0
03-12moomoo
NEXGEL INC - Agreement Anticipated to Increase Annual Revenue to $35 Million and Achieve Profitability at Closing
  • Revenue Expectations: Nexgelin's deal is anticipated to triple its annual revenue to $35 million.
  • Profitability Outlook: The company is expected to become profitable upon closing the deal.
moomoo
7.5
03-12moomoo
NEXGEL INC: $15 Million Upfront Cash and Potential $20 Million in Milestone Payments Included in Consideration
  • Financial Details: The deal includes a $15 million upfront cash payment.
  • Potential Earnings: There is a possibility of up to $20 million in milestone payments.
moomoo
8.5
03-12moomoo
NEXGEL Reveals Terms for Licensing and Acquiring a Portfolio of Commercial Regenerative Biomaterial Products
  • Announcement of Consideration: Nexgel has announced its consideration of terms for an agreement to license and acquire a portfolio of commercial-stage regenerative biomaterial products.

  • Focus on Regenerative Biomaterials: The agreement aims to enhance Nexgel's offerings in the field of regenerative biomaterials, which are used in various medical and commercial applications.

Globenewswire
7.5
03-12Globenewswire
Celularity Forms Strategic Partnership with NEXGEL
  • Strategic Partnership: Celularity's strategic commercialization partnership with NEXGEL aims to leverage renewed regulatory and reimbursement clarity to rapidly enhance market share, with the transaction expected to close by April 15, 2026, marking a significant collaboration in the biomaterials sector.
  • Enhanced Production Capacity: Celularity will exclusively manufacture these biomaterial products at its FDA-compliant facility in Florham Park, New Jersey, utilizing its vertically integrated manufacturing infrastructure designed to support scalable, quality-driven production, which is expected to significantly enhance product competitiveness in the market.
  • Market Potential: The partnership involves established products like Biovance and Natalin, as well as potential disruptors such as SPARK, FUSE, and ORCHID, which are anticipated to generate substantial milestone payments and manufacturing revenues for Celularity, further solidifying its leadership in regenerative medicine.
  • Focus on Core Competencies: CEO Robert J. Hariri emphasized that this partnership allows Celularity to concentrate on its core strength—contract manufacturing—expected to achieve cost efficiencies through effective biomaterial production, thereby driving growth in the biomaterials market.
Benzinga
8.5
03-10Benzinga
NexGel Expects Revenue to Triple
  • Milestone Transaction: NexGel's recent transaction is regarded as a significant milestone in its history, with expected annual revenue reaching approximately $35 million by 2026, nearly tripling current figures, thus enabling immediate profitability and enhancing its position in the medical technology sector.
  • Expanded Product Portfolio: The deal adds six commercially viable regenerative biomaterial products with proven clinical utility, which not only meet market demand but also have insurance reimbursement coverage, thereby supporting a stable revenue base.
  • Future Growth Pipeline: NexGel plans to file three additional 510(k) applications in 2026, 2027, and 2028, providing a visible growth pipeline for its portfolio and further strengthening its competitive edge in the market.
  • Financing and Strategic Investments: The company anticipates closing approximately $14.9 million in financing during the first or early second quarter of 2026, alongside a previously announced financing of about $1.8 million, indicating a proactive approach to acquisitions and enhancing its market expansion capabilities.

Valuation Metrics

The current forward P/E ratio for Nexgel Inc (NXGL.O) is -13.66, compared to its 5-year average forward P/E of -15.49. For a more detailed relative valuation and DCF analysis to assess Nexgel Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-15.49
Current PE
-13.66
Overvalued PE
5.18
Undervalued PE
-36.16

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
25.96
Current EV/EBITDA
329.22
Overvalued EV/EBITDA
117.69
Undervalued EV/EBITDA
-65.77

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
2.43
Current PS
0.94
Overvalued PS
3.81
Undervalued PS
1.06

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

inom den amerikanska marknaden
Intellectia · 15 candidates
Market Cap: <= 1.50BPrice: <= $25.00Beta: HighRiskRsi 14: <= 45Month Price Change Pct: >= $0.00
Ticker
Name
Market Cap$
top bottom
SG logo
SG
Sweetgreen Inc
820.33M
NVX logo
NVX
NOVONIX Ltd
222.62M
LFMD logo
LFMD
LifeMD Inc
170.40M
TMCI logo
TMCI
Treace Medical Concepts Inc
166.30M
HFFG logo
HFFG
Hf Foods Group Inc
116.17M
PYXS logo
PYXS
Pyxis Oncology Inc
103.36M

Whales Holding NXGL

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Nexgel Inc (NXGL) stock price today?

The current price of NXGL is 0.6075 USD — it has decreased -7.88

What is Nexgel Inc (NXGL)'s business?

NexGel, Inc. is a provider of healthcare, beauty, and over-the-counter products, including ultra-gentle, high-water-content hydrogels. It is engaged in manufacturing high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. It specializes in custom gels by capitalizing on proprietary manufacturing technologies. The Company operates through two segments: NexGel and CGN. Its Nexgel segment comprises the manufacturing of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, which is based in Langhorne, Pennsylvania. Its CGN segment comprises CG Converting and Packaging, LLC (CGN), a joint venture with C.G. Laboratories Inc. (CG Labs) used for the Company’s converting and packaging business, which is based in Granbury, Texas. Its brands include Silverseal, Hexagels, Turfguard, Kenkoderm, and Silly George.

What is the price predicton of NXGL Stock?

Wall Street analysts forecast NXGL stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for NXGL is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Nexgel Inc (NXGL)'s revenue for the last quarter?

Nexgel Inc revenue for the last quarter amounts to 2.93M USD, decreased -0.20

What is Nexgel Inc (NXGL)'s earnings per share (EPS) for the last quarter?

Nexgel Inc. EPS for the last quarter amounts to -0.08 USD, decreased -27.27

How many employees does Nexgel Inc (NXGL). have?

Nexgel Inc (NXGL) has 19 emplpoyees as of March 31 2026.

What is Nexgel Inc (NXGL) market cap?

Today NXGL has the market capitalization of 4.95M USD.